Quarterly report pursuant to Section 13 or 15(d)

SEGMENT INFORMATION

v3.22.1
SEGMENT INFORMATION
 6 Months Ended
Apr. 30, 2022
Segment Reporting [Abstract]  
SEGMENT INFORMATION

10. SEGMENT INFORMATION

 

We follow the accounting guidance of ASC 280 “Segment Reporting” (“ASC 280”). Reportable operating segments are determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance. While our results of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in four reportable segments, each with different operating and potential revenue generating characteristics: (i) CAR-T Therapeutics, (ii) Cancer Vaccines, (iii) Anti-Viral Therapeutics and (iv) Other. The following represents selected financial information for our segments for the three and six months ended April 30, 2022 and 2021 and as of April 30, 2022 and October 31, 2021, in thousands:

 

      2022       2021       2022       2021  
    For the Three Months Ended April 30,     For the Six Months
Ended April 30,		  
    2022     2021     2022     2021  
Net Loss:                                
CAR-T Therapeutics   $ (1,399 )   $ (1,446 )   $ (3,010 )   $ (2,406 )
Cancer Vaccines     (1,423 )     (662 )     (2,780 )     (1,569 )
Anti-Viral Therapeutics     (757 )     (310 )     (1,661 )     (791 )
Other     (9 )     (19 )     (16 )     97  
Total   $ (3,588 )   $ (2,437 )   $ (7,467 )   $ (4,669 )
Total operating costs and expenses   $ 3,589     $ 2,437     $ 7,469     $ 5,183  
Less non-cash share-based compensation     (1,681 )     (1,051 )     (4,036 )     (2,037 )
Operating costs and expenses excluding non-cash share-based compensation   $ 1,908     $ 1,386     $ 3,433     $ 3,146  
Operating costs and expenses excluding non-cash share based compensation:                                
CAR-T Therapeutics   $ 759     $ 935     $ 1,427     $ 1,492  
Cancer Vaccines     740       299       1,220       837  
Anti-Viral Therapeutics     402       138       774       409  
Other     7       14       12       408  
Total   $ 1,908     $ 1,386     $ 3,433     $ 3,146  

 

    April 30,
2022		     October 31,
2021		  
Total assets:                
CAR-T Therapeutics   $ 13,014     $ 15,068  
Cancer Vaccines     12,680       13,276  
Anti-Viral Therapeutics     6,883       7,368  
Other     220       545  
Total   $ 32,797     $ 36,257  

 

Operating costs and expenses excluding non-cash share-based compensation is the measurement the chief operating decision-maker uses in managing the enterprise.

 

The Company’s consolidated revenue of $513,000 and inventor royalties, contingent legal fees, litigation and licensing expense of $385,000 for the six months ended April 30, 2021 were solely related to our encrypted audio/video conference calling technology, which is included in our Other segment. All our revenue is generated domestically (United States) based on the country in which the licensee is located.